RxDoctor Payments Data

Stacey Ryan

Psychiatric/Mental Health · Ogdensburg, NYNPI 1427583111

Payments from drug & device makers

$2,619in general payments, 2019–2025

Across 122 payments — averaging $21.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$375
  • Otsuka America Pharmaceutical, Inc.$362
  • Johnson & Johnson$304
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$265
  • Teva Pharmaceuticals USA, Inc.$251
  • Axsome Therapeutics, Inc.$221
  • plus $841 from 6 others

What the payments were for

  • Food & beverage$2,57298%
  • Education$472%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,619 in reported general payments places this provider in the 80th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$11,435
Medicare patients
17
Services billed
175

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate28$83,805
RexultiBrexpiprazole14$28,251
CaplytaLumateperone Tosylate17$25,502
TrintellixVortioxetine Hydrobromide30$18,566
QuviviqDaridorexant Hcl20$9,259
AuvelityDextromethorphan Hbr/Bupropion11$9,050
Aripiprazole33$6,724
Lurasidone Hcl28$6,642
Duloxetine Hcl57$2,358
Sertraline Hcl91$2,119
Quetiapine Fumarate98$1,604
Quetiapine Fumarate ErQuetiapine Fumarate13$1,301
Hydroxyzine Hcl73$1,244
Paroxetine ErParoxetine Hcl23$1,238
Prazosin Hcl57$1,141

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$304$83,80528 claims
Otsuka America Pharmaceutical, Inc.Rexulti$362$28,25114 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$265$25,50217 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$127$18,56630 claims
Idorsia Pharmaceuticals US IncQuviviq$60$9,25920 claims
Axsome Therapeutics, Inc.Auvelity$221$9,05011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in Ogdensburg

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →